Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethics and artificial intelligence.

Revista clinica espanola·2024
Same author

Rotation advancement flap reconstruction following excision of a squamous cell carcinoma in the infraorbital malar region.

Actas dermo-sifiliograficas·2015
Same author

Acute generalized exanthematous pustulosis due to dextromethorphan.

Dermatology online journal·2013
Same author

[The etiology of urinary tract infections and the antimicrobial susceptibility of urinary pathogens].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2005
Same author

[A lung image with cavitation].

Revista clinica espanola·2004
Same author

[Appropriateness of treatment of acute pharyngotonsillitis according to the scientific evidence].

Anales de pediatria (Barcelona, Spain : 2003)·2003

Related Experiment Video

Updated: Jul 11, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

[The antiphospholipid syndrome, an update].

J E Alonso Santor1, L Inglada Galiana, G Pérez Paredes

  • 1Servicio de Medicina Interna, Hospital Universitario Río Hortega, Valladolid, Spain.

Anales De Medicina Interna (Madrid, Spain : 1984)
|October 3, 2007
PubMed
Summary
This summary is machine-generated.

Antiphospholipid syndrome causes blood clots due to antibodies. Treatment for venous clots involves anticoagulants, but arterial clot management in antiphospholipid syndrome requires further research.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: Jul 11, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

  • Immunology
  • Hematology
  • Cardiology

Context:

  • Antiphospholipid syndrome (APS) is an antibody-mediated hypercoagulable state.
  • Characterized by recurrent venous and arterial thromboembolic events.
  • APS occurs in 4-14% of patients with venous thromboembolic events.

Purpose:

  • To review the diagnostic criteria and clinical manifestations of Antiphospholipid syndrome.
  • To discuss current therapeutic recommendations for thromboembolic events in APS.
  • To highlight the need for further research into arterial thromboembolism management in APS.

Summary:

  • Classical APS diagnosis involves anticardiolipin antibodies or lupus anticoagulant, alongside thrombosis or pregnancy loss.
  • Associated conditions include livedo reticularis, thrombocytopenia, valvular heart disease, and nephropathy.
  • Antithrombotic therapy is recommended lifelong after an initial event, with target INR 2.0-3.0 for venous thromboembolism.

Impact:

  • Current guidelines suggest extended antithrombotic therapy for APS patients due to high recurrence risk.
  • Limited data exists for managing initial arterial thromboembolic events in APS.
  • Recurrent events may necessitate immunosuppressive therapies and evaluation of additional prothrombotic risk factors.